Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
about
NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic ImplicationsNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Use of natalizumab in multiple sclerosis: current perspectives.B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity.Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF.Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment.Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients.The chronically inflamed central nervous system provides niches for long-lived plasma cells.Migration against the direction of flow is LFA-1-dependent in human hematopoietic stem and progenitor cells.Systemic bioinformatics analysis of recurrent aphthous stomatitis gene expression profiles.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival.
P2860
Q28078299-400266F0-0E8E-4B4B-AD5D-B5B7EFCEB96CQ30699740-17B6E2ED-F4CF-4688-94BB-1A2925385A95Q31114633-BF3BCCFC-BC2F-498A-BA71-E34ACA205A1CQ37346789-8DF890F2-DD20-4A1D-8E07-6865B101624CQ38401306-663F061C-BCE0-4FBF-9142-03DD5B6E4126Q38801807-F4AF1B8B-DA8C-4689-B1CD-2F130B59002EQ40119805-D00B00C6-AD5B-4CD8-87F3-F2B891DC8ADFQ42350202-5EB512E2-991D-4D9F-AB02-515D6BF48566Q47116115-D30A03F0-0716-4705-A704-067DA6BC27B3Q47309416-F363B7DE-03FE-457D-BC1C-EF74C703807DQ49252202-8928C6B9-D607-4BD8-9A37-DC51A0A82F68Q49884884-CA3AFA42-AF1D-4413-8F05-464447B2B140Q50101803-7EE0BA04-7427-4FB3-A954-798F04D01F46
P2860
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
@en
type
label
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
@en
prefLabel
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
@en
P2860
P50
P356
P1476
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis
@en
P2093
Tilman Schneider-Hohendorf
P2860
P356
10.1093/INTIMM/DXU096
P577
2014-10-17T00:00:00Z